Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2025 16:30 ET | Source: Zymeworks Inc.

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327,...
March 05, 2025 16:05 ET | Source: Zymeworks Inc.

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting...
February 26, 2025 06:00 ET | Source: Zymeworks Inc.

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
February 25, 2025 06:00 ET | Source: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
February 18, 2025 06:00 ET | Source: Zymeworks Inc.

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
February 13, 2025 06:00 ET | Source: Zymeworks Inc.

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
January 30, 2025 06:00 ET | Source: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
January 08, 2025 16:05 ET | Source: Zymeworks Inc.

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025IND applications for initiating first-in-human studies for...
December 12, 2024 08:30 ET | Source: Zymeworks Inc.

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 months ahead of original targetNomination of ZW209, a novel trispecific T cell...
November 21, 2024 06:05 ET | Source: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...